PIK3CA and ovarian carcinoma: A study conducted by Raynaud et al. showed 98% and 80% growth inhibition in PI3K pathway-activated U87MG glioblastoma and IGROV1 ovarian cancer xenograft model confirmed the antitumor activity of Compound 8 (Fig. 2) [38].